BrandWikiReturn

Escitalopram

Escitalopram, sold under the brand names Lexapro and Cipralex, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class. It is mainly used to treat major depressive disorder,[7] generalized anxiety disorder,[7] panic disorder, obsessive–compulsive disorder (OCD), and social anxiety disorder. Escitalopram is taken by mouth.[7] For commercial use, it is formulated as an oxalate salt exclusively.

Common side effects include headache, nausea, sexual problems, mild sedation, and trouble sleeping.[7] In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that escitalopram's product labeling warn of this risk. More serious side effects may include suicidal thoughts in people up to the age of 24 years.[7]

Escitalopram was approved for medical use in the United States in 2002.[7] Escitalopram is rarely replaced by twice the dose of citalopram; escitalopram is safer and more effective.[8] It is on the World Health Organization's List of Essential Medicines.[9] In 2023, it was the second most prescribed antidepressant and fourteenth most commonly prescribed medication in the United States, with more than 37million prescriptions.[10][11] In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023.[12]

Other first-line SSRIs that have similar results include sertraline, paroxetine, and fluoxetine, among others.

Medical uses

Escitalopram is approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder in adolescents and adults, and generalized anxiety disorder (GAD) in adults, in dosage from 5 to 20 mg.[7] In European countries including the United Kingdom, it is approved for depression and anxiety disorders; these include: generalized anxiety disorder, social anxiety disorder (SAD), obsessive–compulsive disorder (OCD), and panic disorder with or without agoraphobia. In Australia it is approved for major depressive disorder.[13][14][15]

Depression

Escitalopram is among the most effective and well-tolerated antidepressants for the short-term treatment of major depressive disorder in adults.[16][17] It also seems to be the safest one to give to children and adolescents.[18][19]

Controversy existed regarding the effectiveness of escitalopram compared with its predecessor, citalopram. The importance of this issue followed from the greater cost of escitalopram relative to the generic mixture of isomers of citalopram, prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. As of 2012, reviews had concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and tolerability.[20][21][22][23]

Anxiety disorders

Escitalopram appears to be effective in treating generalized anxiety disorder, with relapse on escitalopram at 20% rather than placebo at 50%, which translates to a number needed to treat of 3.33.[24][25] Escitalopram appears effective in treating social anxiety disorder as well.[26]

Other

Escitalopram may reduce premenstrual symptoms in women with premenstrual syndrome and premenstrual dysphoric disorder. It seems to be more effective when taken continuously compared to luteal phase administration.[27] It is also occasionally prescribed off-label for insomnia secondary to a mental disorder, and vasomotor symptoms (hot flashes) associated with menopause.

Side effects

Escitalopram has a relatively favorable side effect profile compared to other antidepressant medications. Some of the most common side effects in order of frequency are, headache, nausea, somnolence, insomnia, dry mouth, fatigue, decreased libido, constipation, and flu-like symptoms.

Similar to other SSRIs, escitalopram has been shown to affect sexual function, causing delayed ejaculation, and anorgasmia.[28][29]

There is also evidence that SSRIs are correlated with an increase in suicidal ideation in certain individuals. An analysis conducted by the FDA found a statistically insignificant 1.5 to 2.4-fold (depending on the statistical technique used) increase of suicidality among the adults treated with escitalopram for psychiatric indications.[30][31][32] The authors of a related study note the general problem with statistical approaches: due to the rarity of suicidal events in clinical trials, it is hard to draw firm conclusions with a sample smaller than two million patients.[33]

Citalopram and escitalopram are associated with a mild dose-dependent QT interval prolongation,[34] which is a measure of how rapidly the heart muscle repolarizes after each heartbeat. Prolongation of the QT interval is a risk factor for torsades de pointes (TdP), a heart rhythm disturbance that is sometimes fatal.

Despite the observed change in the QT interval, the risk of TdP from escitalopram appears to be quite low, and it is similar to other antidepressants that are not known to affect the QT interval. A 2013 review[35] discusses several reasons to be optimistic about the safety of escitalopram. It references a crossover study in which 113 subjects were each given four different treatments in randomized order: placebo, 10 mg/day escitalopram, 30 mg/day escitalopram, or 400 mg/day moxifloxacin (a positive control known to cause QTc prolongation). At 10 mg/day, escitalopram increased the QTc interval by 4.5 milliseconds (ms). At 30 mg/day, the QTc increased by 10.7 ms.[36] A QTc increase of less than 60 ms is not likely to confer significant risk.[35] The 30 mg/day escitalopram dose induced significantly less QTc prolongation than a therapeutically equivalent 60 mg/day dose of citalopram, which increased the QTc interval by 18.5 ms.[35]

More data about the cardiac risk from escitalopram can be found in a large observational study from Sweden that took note of all the medications used by all the patients presenting with TdP, and found the incidence of TdP in escitalopram users to be only 0.7 cases of TdP for every 100,000 patients who took the drug (ages 18–64), and only 4.1 cases of TdP for every 100,000 elderly patients who took the drug (ages 65 and up).[37] Of the 9 antidepressants that were used by patients with TdP, escitalopram ranked 7th by TdP incidence in elderly patients (only venlafaxine and amitriptyline had less risk), and it ranked 5th of 9 by TdP incidence in patients ages 18–64.

Antidepressants as a class had a relatively low risk of TdP, and most patients on an antidepressant who experienced TdP were also taking another drug that prolonged QT interval. Specifically, 80% of the escitalopram users who experienced TdP were taking at least one other drug known to cause TdP. For comparison, the most popular antiarrhythmic drug in the study was sotalol with 52,750 users, and sotalol had a TdP incidence of 81.1 cases and 41.2 cases of TdP per 100,000 users in the ≥65 and 18-to-64-year-old demographics, respectively.[37]

Drugs that prolong the QT interval, such as escitalopram, should be used with caution in those with congenital long QT syndrome or known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment. In December 2011, the UK implemented new restrictions on the maximum daily doses at 20 mg for adults and 10 mg for those older than 65 years or with liver impairment.[38][39] The US Food and Drug Administration and Health Canada did not similarly order restrictions on escitalopram dosage, only on its predecessor citalopram.[40]

Like other SSRIs, escitalopram has also been reported to cause hyponatremia (low sodium levels), with rates ranging from 0.5 to 32%, which can often be attributed to SIADH.[41] This is typically not dose-dependent and at higher risk for occurrence within the first few weeks of starting treatment.[42]

Like other SSRIs, escitalopram often exacerbates symptoms of mania and hypomania in individuals misdiagnosed with a depressive disorder instead of a bipolar disorder, making it crucial for clinicians to rule out bipolar disorders before prescribing escitalopram.

Very common effects

Very common effects (>10% incidence) include:[43][44][45][3][46]

  • Headache (24%)
  • Nausea (18%)
  • Ejaculation disorders (9–14%)
  • Somnolence (4–13%)
  • Insomnia (7–12%)

Common (1–10% incidence)

Common effects (1–10% incidence) include:

  • Abnormal dreams
  • Anisocoria
  • Anorgasmia
  • Anxiety
  • Arthralgia (joint pain)
  • Constipation
  • Decreased or increased appetite
  • Diarrhea
  • Dilated pupils
  • Dizziness
  • Dry mouth
  • Excessive sweating
  • Fatigue
  • Fever
  • Impotence (erectile dysfunction)
  • Libido changes
  • Myalgia (muscular aches and pains)
  • Paraesthesia (abnormal skin sensation)
  • Restlessness
  • Sinusitis (nasal congestion)
  • Tremor
  • Vomiting
  • Yawning

Psychomotor effects

The most common effect is fatigue or somnolence, particularly in older adults,[47] although patients with pre-existing daytime sleepiness and fatigue may experience paradoxical improvement of these symptoms.[48]

Escitalopram has not been shown to affect serial reaction time, logical reasoning, serial subtraction, multitasking, or Mackworth Clock task performance.[49]

Post-SSRI sexual dysfunction

Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including escitalopram.[50][51] Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur.[51] The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment.[52] The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued.[53][54]

A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported.[55] A 2023 systematic review found that escitalopram was the single most frequently reported SSRI in PSSD case reports, followed by citalopram, paroxetine, sertraline, and fluoxetine.[56]

In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that product labels for all SSRIs and SNRIs, including escitalopram, be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped.[57] Health Canada followed with similar label updates in 2021.[54] In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk.[58]

Pregnancy

Antidepressant exposure (including escitalopram) is associated with shorter duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points). Antidepressant exposure is not associated with an increased risk of spontaneous abortion.[59] There is a tentative association of SSRI use during pregnancy with heart problems in the baby. The advantages of their use during pregnancy may thus not outweigh the possible negative effects on the baby.[60]

Withdrawal

Escitalopram discontinuation, particularly abruptly, may cause certain withdrawal symptoms such as "electric shock" sensations,[61] colloquially called "brain shivers" or "brain zaps" by those affected. Frequent symptoms in one study were dizziness (44%), muscle tension (44%), chills (44%), confusion or trouble concentrating (40%), amnesia (28%), and crying (28%). Very slow tapering is recommended.[62]

There have been spontaneous reports of discontinuation of escitalopram and other SSRIs and SNRIs, especially when abrupt, leading to dysphoric mood, irritability, agitation, anxiety, headache, lethargy, emotional lability, insomnia, and hypomania. Other symptoms such as panic attacks, hostility, aggression, impulsivity, akathisia (psychomotor restlessness), mania, worsening of depression, and suicidal ideation can emerge when the dose is adjusted down.[63]

Overdose

Excessive doses of escitalopram usually cause relatively minor untoward effects, such as agitation and tachycardia. However, dyskinesia, hypertonia, and clonus may occur in some cases. Severe side effects of escitalopram overdose include seizures (which may be delayed), cardiovascular toxicity including QRS/QTc prolongation which can lead to arrhythmias (Torsades de pointes, ventricular fibrillation, and ventricular tachycardia), hypertension, and serotonin syndrome. Treatment of escitalopram overdoses typically involves supportive care, such as giving Activated charcoal or giving benzodiazepines for seizures.[64] Because of the risk of arrhythmias (which may be delayed) prolonged cardiac monitoring is strongly recommended[64]

Interactions

Escitalopram weakly inhibits CYP2D6, and hence may increase plasma levels of some CYP2D6 substrates such as aripiprazole, risperidone, tramadol, or codeine.[5] As escitalopram is only a weak inhibitor of CYP2D6, analgesia from tramadol may not be affected.[65] Escitalopram (at the maximum dose of 20mg/day) has been found to increase peak levels of the CYP2D6 substrate desipramine by 40% and total exposure by 100%.[6] Likewise, it has been found to increase peak levels of the CYP2D6 substrate metoprolol by 50% and overall exposure by 82%.[6] Escitalopram does not inhibit CYP3A4, CYP1A2, CYP2C9, CYP2C19, or CYP2E1.[5][6]

Exposure to escitalopram is increased moderately, by about 50%, when it is taken with omeprazole, a CYP2C19 inhibitor.[5] The authors of this study suggested that this increase is unlikely to be of clinical concern.[66] Combination of citalopram with fluoxetine or fluvoxamine resulted in increased exposure to the escitalopram enantiomer, owing to the strong inhibition of CYP2C19 and CYP2D6 by these agents.[6]

Bupropion, a known strong CYP2D6 inhibitor, has been found to significantly increase citalopram plasma concentration and systemic exposure (peak levels increased by 30%, total exposure increased by 40%); as of April 2018 the interaction with escitalopram had not been studied, but some monographs warned of the potential interaction.[67] Citalopram did not affect the pharmacokinetics of bupropion or its metabolites in the study.[67]

Escitalopram should be taken with caution when using St. John's wort, ginseng, dextromethorphan, linezolid, tramadol, and other serotonergic drugs due to the risk of serotonin syndrome.[68][69] As an SSRI, escitalopram should not be given concurrently with MAOIs.

Escitalopram, similarly to other SSRIs, may increase bleeding risk with NSAIDs (e.g., ibuprofen, naproxen, mefenamic acid), antiplatelet drugs, anticoagulants, omega-3 fatty acids, vitamin E, and garlic supplements due to escitalopram's inhibitory effects on platelet aggregation via blocking serotonin transporters on platelets.[70]

Escitalopram can also prolong the QT interval, and hence it is not recommended in patients who are concurrently on other medications that also can prolong the QT interval. These drugs include antiarrhythmics, antipsychotics, tricyclic antidepressants, some antihistamines (e.g., astemizole, mizolastine), macrolide and fluoroquinolone antibiotics, some 5-HT3 receptor antagonists (except palonosetron), and some antiretrovirals (e.g., ritonavir, saquinavir, lopinavir).[38]

Pharmacology

Mechanism of action

Escitalopram increases intrasynaptic levels of the neurotransmitter serotonin by blocking the reuptake of the neurotransmitter into the presynaptic neuron. Over time, this leads to a downregulation of pre-synaptic 5-HT1A receptors, which is associated with an improvement in passive stress tolerance, and delayed downstream increase in expression of brain-derived neurotrophic factor, which may contribute to a reduction in negative affective biases.[73][74]

Of the SSRIs currently available, escitalopram has the highest selectivity for the serotonin transporter (SERT) compared to the norepinephrine transporter (NET), making the side-effect profile relatively mild in comparison to less-selective SSRIs.[75] In addition to its antagonist action at the orthosteric site of SERT, escitalopram also binds to an allosteric site on the transporter, thereby decreasing its disassociation rate.[76] Escitalopram binds to this allosteric site at a greater affinity than other SSRIs.[77] The clinical relevance of this action is unknown.

Pharmacokinetics

Escitalopram is a substrate of P-glycoprotein and hence P-glycoprotein inhibitors such as verapamil and quinidine may improve its blood-brain barrier penetrability. In a preclinical study in rats combining escitalopram with a P-glycoprotein inhibitor, its antidepressant-like effects were enhanced.[78]

Chemistry

Escitalopram is the (S)-enantiomer (left-handed version) of the racemate citalopram, which is responsible for its name: escitalopram.[7][79]

History

Escitalopram was developed in cooperation between Lundbeck and Forest Laboratories. Its development was initiated in 1997, and the resulting new drug application was submitted to the US FDA in March 2001. The short time (3.5 years) it took to develop escitalopram can be attributed to the previous experience of Lundbeck and Forest with citalopram, which has similar pharmacology.[80]

Society and culture

Brand names

Escitalopram is sold under many brand names worldwide such as Cipralex, Lexapro, Lexam, Mozarin, Aciprex, Depralin, Ecytara, Elicea, Gatosil, Nexpram, Nexito, Nescital, Szetalo, Stalopam, Pramatis, Betesda, Scippa and Rexipra.[81][82]

Legal status

The FDA issued the approval of escitalopram for major depression in August 2002, and for generalized anxiety disorder in December 2003. In May 2006, the FDA approved a generic version of escitalopram by Teva.[83] In July 2006, the U.S. District Court of Delaware decided in favor of Lundbeck regarding a patent infringement dispute and ruled the patent on escitalopram valid.[84]

In 2006, Forest Laboratories was granted an 828-day (2 years and 3 months) extension on its US patent for escitalopram.[85] This pushed the patent expiration date from 7 December 2009, to 14 September 2011. Together with the 6-month pediatric exclusivity, the final expiration date was 14 March 2012.

Allegations of illegal marketing

In 2004, separate civil suits alleging illegal marketing of citalopram and escitalopram for use by children and teenagers by Forest were initiated by two whistleblowers: a physician named Joseph Piacentile and a Forest salesman named Christopher Gobble.[86] In February 2009, the suits were joined. Eleven states and the District of Columbia filed notices of intent to intervene as plaintiffs in the action.

The suits alleged that Forest illegally engaged in off-label promotion of Lexapro for use in children; hid the results of a study showing lack of effectiveness in children; paid kickbacks to physicians to induce them to prescribe Lexapro to children; and conducted so-called "seeding studies" that were, in reality, marketing efforts to promote the drug's use by doctors.[87][88] Forest denied the allegations[89] but ultimately agreed to settle with the plaintiffs for over $313 million.[90]

See also

  • List of antidepressants

External links

References

  1. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 Therapeutic Goods Administration (TGA), 21 June 2022, retrieved 30 March 2024^
  2. Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial Diário Oficial da União, 31 March 2023, retrieved 3 August 2023^
  3. Lexapro- escitalopram tablet, film coated; Lexapro- escitalopram solution DailyMed, 17 November 2023, retrieved 31 December 2023^
  4. Human Medicine Division. Active substance(s): escitalopram List of nationally authorised medicinal products, European Medicines Agency, September 2022, retrieved 6 September 2022^
  5. Clinical pharmacology review of escitalopram for the treatment of depression Expert Opin Drug Metab Toxicol, January 2014^
  6. The clinical pharmacokinetics of escitalopram Clin Pharmacokinet, 2007^
  7. Escitalopram (Monograph) The American Society of Health-System Pharmacists, retrieved 28 December 2017^
  8. Protocol for switching patients from escitalopram to citalopram NHS, 2015, retrieved 13 February 2018^
  9. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) World Health Organization, 2023^
  10. Top 300 of 2023 ClinCalc, retrieved 12 August 2025^
  11. Escitalopram Drug Usage Statistics, United States, 2014 - 2023 ClinCalc, retrieved 12 August 2025^
  12. Medicines in the health system Australian Institute of Health and Welfare, 2 July 2024, retrieved 30 September 2024^
  13. Escitalopram oxalate Australian Prescriber, 2003, retrieved 15 March 2020^
  14. Lundbeck's Cipralex gets EU ok for OCD treatment Reuters, 12 January 2007, retrieved 15 March 2020^
  15. Cipralex 10 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc) www.medicines.org.uk, retrieved 15 March 2020^
  16. The most effective antidepressants for adults revealed in major review NIHR Evidence, National Institute for Health and Care Research, 3 April 2018^
  17. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, April 2018^
  18. Psychiatric drugs given to children and adolescents have been ranked in order of safety NIHR Evidence, National Institute for Health and Care Research, 1 September 2020^
  19. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects World Psychiatry, June 2020^
  20. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model PLOS ONE, 2012^
  21. Citalopram versus other anti-depressive agents for depression The Cochrane Database of Systematic Reviews, July 2012^
  22. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram] L'Encéphale, February 2012^
  23. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences Current Medical Research and Opinion, December 2010^
  24. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis Lancet, February 2019^
  25. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder The Journal of Clinical Psychiatry, February 2010^
  26. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo European Neuropsychopharmacology, June 2016^
  27. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder The Cochrane Database of Systematic Reviews, August 2024^
  28. Burden of phase-specific sexual dysfunction with SSRIs Journal of Affective Disorders, March 2006^
  29. Lexapro prescribing information retrieved 23 August 2017^
  30. Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006) Food and Drug Administration, retrieved 13 May 2007^
  31. Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults Overview for 13 December Meeting of Pharmacological Drugs Advisory Committee (PDAC), FDA, 17 November 2006, retrieved 22 September 2007^
  32. Statistical Evaluation of Suicidality in Adults Treated with Antidepressants Overview for 13 December Meeting of Pharmacological Drugs Advisory Committee (PDAC), FDA, 17 November 2006, retrieved 22 September 2007^
  33. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports Annals of Clinical Psychiatry, 2007^
  34. QT interval and antidepressant use: a cross sectional study of electronic health records BMJ, January 2013^
  35. Antidepressants and QTc prolongation Journal of Psychiatry & Neuroscience, March 2013^
  36. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses US FDA, 15 December 2017, retrieved 1 May 2024^
  37. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study BMJ Open, March 2020^
  38. Citalopram and escitalopram: QT interval prolongation—new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings Medicines and Healthcare products Regulatory Agency, December 2011, retrieved 5 March 2013^
  39. Clinical and ECG effects of escitalopram overdose Annals of Emergency Medicine, September 2009^
  40. Escitalopram and QTc prolongation Journal of Psychiatry & Neuroscience, July 2013^
  41. Antidepressants and the risk of hyponatremia: a Danish register-based population study BMJ Open, May 2016^
  42. Escitalopram Dose-Dependent Hyponatremia Journal of Clinical Pharmacology, June 2018^
  43. Lexapro (escitalopram) dosing, indications, interactions, adverse effects, and more Medscape, retrieved 9 April 2025^
  44. Cipralex 5, 10 and 20 mg film-coated tablets - Summary of Product Characteristics (SPC) electronic Medicines Compendium, 2 October 2013, retrieved 27 November 2013^
  45. Escitalopram-Lupin Tablets (LUPIN AUSTRALIA PTY. LTD) TGA eBusiness Services, Lupin Australia Pty Ltd, 21 December 2011, retrieved 27 November 2013^
  46. Unequal Sized Pupils Due to Escitalopram; Adverse Events to Dietary Supplements Causing Emergency Department Visits; Compulsive Masturbation Due to Pramipexole; Metformin-Induced Lactic Acidosis Masquerading As an Acute Myocardial Infarction Hospital Pharmacy, Thomas Land Publishers, Inc., May 2016^
  47. Escitalopram Treatment of Generalized Anxiety Disorder in Older Adults—Reply JAMA, 20 May 2009^
  48. Excessive daytime sleepiness and fatigue in depressed patients and therapeutic response of a sedating antidepressant Journal of Affective Disorders, November 2011^
  49. Alertness management in aviation operations: enhancing performance and sleep Aviation, Space, and Environmental Medicine, December 2006^
  50. Post-SSRI Sexual Dysfunction: A Literature Review Sexual Medicine Reviews, January 2018^
  51. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin International Journal of Risk & Safety in Medicine, 2022^
  52. Enduring sexual dysfunction after treatment with antidepressants, 5-alpha-reductase inhibitors and isotretinoin: 300 cases International Journal of Risk & Safety in Medicine, 2018^
  53. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Publishing, 2013^
  54. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence Epidemiology and Psychiatric Sciences, 2024^
  55. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants Annals of General Psychiatry, April 2023^
  56. Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: A systematic review Pharmacoepidemiology and Drug Safety, October 2023^
  57. PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting European Medicines Agency, 11 June 2019, retrieved 8 April 2026^
  58. Updated warnings about persistent sexual dysfunction for antidepressants Therapeutic Goods Administration, 23 May 2024, retrieved 8 April 2026^
  59. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis JAMA Psychiatry, April 2013^
  60. Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms Expert Opinion on Drug Metabolism & Toxicology, 1 July 2015^
  61. Emergence of electric shock-like sensations on escitalopram discontinuation Journal of Clinical Psychopharmacology, June 2008^
  62. Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study Clinical Neuropharmacology, June 2016^
  63. Lexapro (Escitalopram Oxalate) Drug Information: Warnings and Precautions - Prescribing Information at RxList retrieved 9 August 2015^
  64. Lexapro prescribing guide Allergan^
  65. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain Clinical Pharmacology and Therapeutics, December 2009^
  66. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects British Journal of Clinical Pharmacology, September 2005^
  67. Drug interactions between bupropion and Lexapro Drugs.com, retrieved 22 April 2018^
  68. 2006 Lippincott's Nursing Drug Guide Lippincott Williams & Wilkins, 2006^
  69. The serotonin syndrome The New England Journal of Medicine, March 2005^
  70. UpToDate www.uptodate.com, retrieved 10 August 2022^
  71. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? International Clinical Psychopharmacology, July 2014^
  72. Escitalopram block of hERG potassium channels Naunyn-Schmiedeberg's Archives of Pharmacology, January 2014^
  73. Serotonin and brain function: a tale of two receptors Journal of Psychopharmacology, September 2017^
  74. How do antidepressants work? New perspectives for refining future treatment approaches The Lancet. Psychiatry, May 2017^
  75. Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.^
  76. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action Psychopharmacology, January 2012^
  77. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies The International Journal of Neuropsychopharmacology, February 2007^
  78. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents Neuropsychopharmacology, October 2013^
  79. Meyler's Side Effects of Drugs Elsevier, 2016^
  80. 2000 Annual Report. p 28 and 33 Lundbeck, 2000, retrieved 7 April 2007^
  81. Escitalopram Drugs.com International, retrieved 25 April 2015^
  82. Mozarin, zamienniki i podobne rodukty Gdziepolek.pl, retrieved 17 October 2020^
  83. FDA OKs Generic Depression Drug – Generic Version of Lexapro Gets Green Light WebMD, retrieved 10 October 2007^
  84. US court upholds Lexapro patent FirstWord, 14 July 2006, retrieved 10 October 2007^
  85. Forest Laboratories Receives Patent Term Extension for Lexapro PRNewswire-FirstCall, 2 March 2006, retrieved 19 January 2009^
  86. Forest Laboratories: A Tale of Two Whistleblowers The American Lawyer, 27 February 2009^
  87. United States of America v. Forest Laboratories US District Court for the district of Massachusetts^
  88. Drug Maker Is Accused of Fraud The New York Times, 25 February 2009^
  89. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government Forest Laboratories, 26 February 2009^
  90. Drug Maker Forest Pleads Guilty; To Pay More Than $313 Million to Resolve Criminal Charges and False Claims Act Allegations www.justice.gov, 15 September 2010, retrieved 22 November 2020^